Physician profile
Renaldo Jacques
NPI 1477528974
$933.88
in general payments reported to CMS, 2019-2025
17 companies · $20.19 in 2025
The $20.19 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $112 · 2023: $137 · 2025: $20.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $122.51 | 2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $121.43 | 2019 | |
| Radius Health, INC. | $117.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $87.62 | 2019 | |
| Pfizer INC. | $81.53 | 2019-2020 | |
| Si-Bone, INC. | $73.85 | 2019 | |
| Allergan, INC. | $69.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $40.51 | 2019-2020 | |
| Edwards Lifesciences Corporation | $34.45 | 2023-2025 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $29.31 | 2019 | |
| Amarin Pharma, INC. | $28.02 | 2019-2020 | |
| Novo Nordisk INC | $26.66 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2019 | |
| Astellas Pharma US INC | $12.91 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.57 | 2019 | |
| Ironshore Pharmaceuticals INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renaldo Jacques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.